MWNA
AUTL

Marshall Wace North America’s Autolus Therapeutics AUTL Stock Holding History

Marshall Wace North America’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-980
Closed -$13K – 1224
2019
Q4 		$13K Buy
+980
New +$12.8K ﹤0.01% 1219
2018
Q4 		– Sell
-19,811
Closed -$597K – 1466
2018
Q3 		$597K Sell
19,811
-15,789
-44% -$426K ﹤0.01% 679
2018
Q2 		$954K Buy
+35,600
New +$941K 0.01% 941

Other funds holding AUTL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Marshall Wace North America's AUTL Position: Q1 2020 in Review

Marshall Wace North America sold out of Autolus Therapeutics (AUTL) in Q1 2020, closing a stake of 980 shares — an estimated $13K sold.

Marshall Wace North America first reported a position in AUTL in Q2 2018 and held it in 3 quarters. The position peaked at $954K in Q2 2018. 51 funds tracked by Wall St. Rank hold AUTL as of Q1 2020.

  • Marshall Wace North America reported no remaining Autolus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace North America sold 980 Autolus Therapeutics shares in Q1 2020, an estimated $13K.
  • Marshall Wace North America first reported a position in Autolus Therapeutics in Q2 2018 and held it in 3 quarters.
  • Marshall Wace North America's Autolus Therapeutics position peaked at $954K in Q2 2018.
  • 51 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.